AAAAAA
Results: 1-25/28
Authors:
Diaz, E
Levine, HB
Sullivan, MC
Sernyak, MJ
Hawkins, KA
Cramer, JA
Woods, SW
Citation: E. Diaz et al., Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia, J PSYCH NEU, 26(4), 2001, pp. 325-329
Authors:
Woods, SW
Miller, TJ
Davidson, L
Hawkins, KA
Sernyak, MJ
McGlashan, TH
Citation: Sw. Woods et al., Estimated yield of early detection of prodromal or first episode patients by screening first degree relatives of schizophrenic patients, SCHIZOPHR R, 52(1-2), 2001, pp. 21-27
Authors:
Baker, CB
Woods, SW
Citation: Cb. Baker et Sw. Woods, Cost of treatment failure for major depression: Direct costs of continued treatment, ADM POL M H, 28(4), 2001, pp. 263-277
Authors:
Morgenstern, H
Glazer, WM
Woods, SW
Citation: H. Morgenstern et al., Risperidone and tardive dyskinesia, INT J GER P, 16(5), 2001, pp. 541-542
Authors:
Asnis, GM
Hameedi, FA
Goddard, AW
Potkin, SG
Black, D
Jameel, M
Desagani, K
Woods, SW
Citation: Gm. Asnis et al., Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients, PSYCHIAT R, 103(1), 2001, pp. 1-14
Authors:
Gelernter, J
Bonvicini, K
Page, G
Woods, SW
Goddard, AW
Kruger, S
Pauls, DL
Goodson, S
Citation: J. Gelernter et al., Linkage genome scan for loci predisposing to panic disorder or agoraphobia, AM J MED G, 105(6), 2001, pp. 548-557
Authors:
Huppert, JD
Bufka, LF
Barlow, DH
Gorman, JM
Shear, MK
Woods, SW
Citation: Jd. Huppert et al., Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder, J CONS CLIN, 69(5), 2001, pp. 747-755
Authors:
Woods, SW
Stolar, M
Sernyak, MJ
Charney, DS
Citation: Sw. Woods et al., Consistency of atypical antipsychotic superiority to placebo in recent clinical trials, BIOL PSYCHI, 49(1), 2001, pp. 64-70
Authors:
Goddard, AW
Brouette, T
Almai, A
Jetty, P
Woods, SW
Charney, D
Citation: Aw. Goddard et al., Early coadministration of clonazepam with sertraline for panic disorder, ARCH G PSYC, 58(7), 2001, pp. 681-686
Authors:
Glazer, WM
Woods, SW
Citation: Wm. Glazer et Sw. Woods, Should sisyphus have taken melatonin?, ARCH G PSYC, 58(11), 2001, pp. 1054-1055
Authors:
Woods, SW
Money, R
Baker, CB
Citation: Sw. Woods et al., Does the manic/mixed episode distinction in bipolar disorder patients run true over time?, AM J PSYCHI, 158(8), 2001, pp. 1324-1326
Authors:
Woods, SW
Citation: Sw. Woods, A patient with bipolar disorder receiving maintenance therapy with antipsychotic medication was recently transferred to my care. Should I maintain the antipsychotic or taper it?, J PSYCH NEU, 25(1), 2000, pp. 64-64
Authors:
Woods, SW
Citation: Sw. Woods, Pharmacoeconomic studies of antidepressants: Focus on venlafaxine, DEPRESS ANX, 12, 2000, pp. 102-109
Effects of divalproex versus lithium on length of hospital stay among patients with bipolar disorder
Authors:
Dalkilic, A
Diaz, E
Baker, CB
Pearsall, HR
Woods, SW
Citation: A. Dalkilic et al., Effects of divalproex versus lithium on length of hospital stay among patients with bipolar disorder, PSYCH SERV, 51(9), 2000, pp. 1184-1186
Authors:
Woods, SW
Ziedonis, DM
Sernyak, MJ
Diaz, E
Rosenheck, RA
Citation: Sw. Woods et al., Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia, PSYCH SERV, 51(1), 2000, pp. 79-84
Authors:
Vythilingam, M
Anderson, ER
Goddard, A
Woods, SW
Staib, LH
Charney, DS
Bremner, JD
Citation: M. Vythilingam et al., Temporal lobe volume in panic disorder - a quantitative magnetic resonanceimaging study, PSYCH RES-N, 99(2), 2000, pp. 75-82
Authors:
Woods, SW
Citation: Sw. Woods, The economic burden of bipolar disease, J CLIN PSY, 61, 2000, pp. 38-41
Authors:
Barlow, DH
Gorman, JM
Shear, MK
Woods, SW
Citation: Dh. Barlow et al., Cognitive-behavioral therapy, imipramine, or their combination for panic disorder (vol 283, pg 2529, 2000), J AM MED A, 284(19), 2000, pp. 2450-2450
Authors:
Barlow, DH
Gorman, JM
Shear, MK
Woods, SW
Citation: Dh. Barlow et al., Cognitive-behavioral therapy, imipramine, or their combination for panic disorder - A randomized controlled trial, J AM MED A, 283(19), 2000, pp. 2529-2536
Authors:
Winther, LC
Saleem, R
McCance-Katz, EF
Rosen, MI
Hameedi, FA
Pearsall, HR
Jatlow, PI
Kosten, TR
Woods, SW
Citation: Lc. Winther et al., Effects of lamotrigine on behavioral and cardiovascular responses to cocaine in human subjects, AM J DRUG A, 26(1), 2000, pp. 47-59
Authors:
Kosten, TR
Woods, SW
Rosen, MI
Pearsall, HR
Citation: Tr. Kosten et al., Interactions of cocaine with nimodipine: A brief report, AM J ADDICT, 8(1), 1999, pp. 77-81
Authors:
Goddard, AW
Woods, SW
Money, R
Pande, AC
Charney, DS
Goodman, WK
Heninger, GR
Price, LH
Citation: Aw. Goddard et al., Effects of the CCKB antagonist CI-988 on responses to mCPP in generalized anxiety disorder, PSYCHIAT R, 85(3), 1999, pp. 225-240
Authors:
Hawkins, KA
Mohamed, S
Woods, SW
Citation: Ka. Hawkins et al., Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?, PSYCHOL MED, 29(1), 1999, pp. 1-8
Authors:
Miller, TJ
McGlashan, TH
Woods, SW
Stein, K
Driesen, N
Corcoran, CM
Hoffman, R
Davidson, L
Citation: Tj. Miller et al., Symptom assessment in schizophrenic prodromal states, PSYCHIAT Q, 70(4), 1999, pp. 273-287
Authors:
Fujita, M
Woods, SW
Verhoeff, NPLG
Abi-Dargham, A
Baldwin, RM
Zoghbi, SS
Soares, JC
Jatlow, PA
Krystal, JH
Rajeevan, N
Charney, DS
Seibyl, JP
Innis, RB
Citation: M. Fujita et al., Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans, EUR J PHARM, 368(2-3), 1999, pp. 161-172